Skip to main content
. 2022 Mar 16;28(14):3002–3010. doi: 10.1158/1078-0432.CCR-21-3872

Figure 1.

Figure 1. Study design. BINI, binimetinib; RIBO, ribociclib.

Study design. BID, twice daily; BINI, binimetinib; PR, partial response; QD, once daily; RIBO, ribociclib.